Vivoryon Therapeutics N.V. reports successful shift to kidney disease treatment with positive financial and operational updates.

From GlobeNewswire: 2025-04-29 01:00:00

Vivoryon Therapeutics N.V. reported full-year 2024 financial results and highlighted a successful strategic shift towards kidney disease treatment. Their Phase 2 program for varoglutamstat showed significant improvement in kidney function compared to a placebo. The company also received a new patent for varoglutamstat in the U.S. and entered a financial agreement for up to EUR 15 million with Yorkville Advisors Global, LP.

The company’s strategic shift to focus on inflammatory and fibrotic diseases, especially kidney disease, led to positive results in clinical studies. Varoglutamstat, a potent inhibitor of key enzymes, showed consistent improvement in kidney function in patients with diabetes. The results were presented at various conferences, showcasing the potential for treating diabetic kidney disease.

Pre-clinical data revealed a synergistic effect of combining varoglutamstat with an SGLT2 inhibitor, showing promising results in animal models of chronic kidney disease. The company aims to advance varoglutamstat in kidney disease treatment through a Phase 2b clinical study in patients with advanced diabetic kidney disease.

Vivoryon also strengthened its IP with new patents and announced a new management addition, Julia Neugebauer. Financially, the company expects its current cash reserves to fund operations until January 2026. The company is actively exploring additional funding options to support its kidney disease strategy and future operations.

For more information, including financial statements and contact details, refer to Vivoryon Therapeutics N.V.’s press release.



Read more at GlobeNewswire:: Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial